Li Shangkun, Min Su, Wu Bin, Tang Wanbi
Department of Anesthesiology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
Department of Anesthesiology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China. Email:
Zhonghua Shao Shang Za Zhi. 2015 Feb;31(1):48-51.
To evaluate the efficacy and safety of patient-controlled intravenous analgesia (PCIA) of dezocine combined with sufentanil in burn patients after escharectomy or tangential excision followed by autologous skin grafting.
Sixty burn patients hospitalized in Department of Burns and Plastic Surgery of our hospital from February 2011 to December 2013, conforming to the study criteria and going to have escharectomy or tangential excision followed by autologous skin grafting, were divided into sufentanil group (S, n = 30) and dezocine+sufentanil group (DS, n = 30) according to the random number table. Patients in group S were given 150 mL normal saline containing 2.5 µg/kg sufentanil citrate and 6 mg tropisetron after skin grafting for 48 hours. Patients in group DS were given 150 mL normal saline containing 0.25 mg/kg dezocine, 1.5 µg/kg sufentanil citrate, and 6 mg tropisetron for 48 hours. Visual Analog Scale (VAS), Bruggrmann Comfort Scale (BCS), and Ramsay Sedation Scale were used to evaluate the sedative effect or analgesic effect, and their scores were recorded at administration hour (AH) 2, 6, 12, 24, and 48. The times of efficient injection and incidence of adverse effect within the 48 AH were recorded. Data were processed with analysis of variance for repeated measurement, t test, chi-square test, and Fisher's exact test.
There were no obvious differences in the scores of VAS and BCS between two groups at each time point (with t values from -0.426 to 0.864, P values above 0.05). The scores of Ramsay Sedation Scale in group S at AH 2, 6, 12, 24, and 48 were respectively (3.2 ± 0.6), (3.2 ± 0.5), (3.3 ± 0.7), (3.2 ± 0.4), and (3.3 ± 0.4) points, which were higher than those in group DS [(2.4 ± 0.6), (2.5 ± 0.5), (2.4 ± 0.6), (2.4 ± 0.4), and (2.4 ± 0.5) points, with t values from 5.302 to 8.391, P values below 0.001]. The times of efficient injection within the 48 AH was 6.8 ± 0.7 in group S and 6.5 ± 0.9 in group DS, showing no significantly statistical difference (t = 1.260, P > 0.05). Respiratory depression was not observed in both groups; the incidence of pruritus was the same, and that of urine retention was similar between the 2 groups within the 48 AH (with P values above 0.05). Within the 48 AH, the incidence of nausea and vomiting in group S was 26.7% (8/30), which was obviously higher than that in group DS (6.7%, 2/30, P < 0.05); the incidence of drowsiness in group S was 20.0% (6/30), which was significantly higher than that in group DS (no patient, P < 0.05).
Dezocine combined with sufentanil can provide effective postoperative analgesia with little adverse effect for PCIA in burn patients after escharectomy or tangential excision followed by autologous skin grafting, therefore it can be widely used.
评价地佐辛联合舒芬太尼用于烧伤患者切痂或削痂加自体皮移植术后自控静脉镇痛(PCIA)的有效性和安全性。
选取2011年2月至2013年12月在我院烧伤整形科住院、符合研究标准且拟行切痂或削痂加自体皮移植术的60例烧伤患者,按随机数字表法分为舒芬太尼组(S组,n = 30)和地佐辛 + 舒芬太尼组(DS组,n = 30)。S组患者在植皮术后48小时给予含2.5 μg/kg枸橼酸舒芬太尼和6 mg托烷司琼的150 mL生理盐水。DS组患者给予含0.25 mg/kg地佐辛、1.5 μg/kg枸橼酸舒芬太尼和6 mg托烷司琼的150 mL生理盐水,持续48小时。采用视觉模拟评分法(VAS)、Bruggrmann舒适量表(BCS)和Ramsay镇静量表评估镇静或镇痛效果,并于给药后2、6、12、24和48小时记录其评分。记录48小时内有效按压次数及不良反应发生率。数据采用重复测量方差分析、t检验、卡方检验和Fisher确切概率法进行处理。
两组各时间点VAS和BCS评分比较,差异均无统计学意义(t值为 -0.426至0.864,P值均>0.05)。S组给药后2、6、12、24和48小时的Ramsay镇静量表评分分别为(3.2 ± 0.6)、(3.2 ± 0.5)、(3.3 ± 0.7)、(3.2 ± 0.4)和(3.3 ± 0.4)分,高于DS组[(2.4 ± 0.6)、(2.5 ± 0.5)、(2.4 ± 0.6)、(2.4 ± 0.4)和(2.4 ± 0.5)分,t值为5.302至8.391,P值均<0.001]。48小时内S组有效按压次数为6.8 ± 0.7次,DS组为6.5 ± 0.9次,差异无统计学意义(t = 1.260,P>0.05)。两组均未观察到呼吸抑制;瘙痒发生率相同,48小时内两组尿潴留发生率相近(P值均>0.05)。48小时内,S组恶心呕吐发生率为26.7%(8/30),明显高于DS组(6.7%,2/30,P<0.05);S组嗜睡发生率为20.0%(6/30),明显高于DS组(无患者发生,P<0.05)。
地佐辛联合舒芬太尼用于烧伤患者切痂或削痂加自体皮移植术后PCIA,可提供有效的术后镇痛,不良反应少,可广泛应用。